311 related articles for article (PubMed ID: 24814395)
1. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
2. JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis.
Heinicke U; Kupka J; Fulda S
Oncotarget; 2015 Nov; 6(35):37836-51. PubMed ID: 26473375
[TBL] [Abstract][Full Text] [Related]
3. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
4. Critical role of mitochondria-mediated apoptosis for JNJ-26481585-induced antitumor activity in rhabdomyosarcoma.
Heinicke U; Kupka J; Fichter I; Fulda S
Oncogene; 2016 Jul; 35(28):3729-41. PubMed ID: 26616861
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
[TBL] [Abstract][Full Text] [Related]
6. BCL-x
Faqar-Uz-Zaman SF; Heinicke U; Meister MT; Vogler M; Fulda S
Cancer Lett; 2018 Jan; 412():131-142. PubMed ID: 28947136
[TBL] [Abstract][Full Text] [Related]
7. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
[TBL] [Abstract][Full Text] [Related]
8. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
10. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.
Häcker S; Karl S; Mader I; Cristofanon S; Schweitzer T; Krauss J; Rutkowski S; Debatin KM; Fulda S
Oncogene; 2011 May; 30(19):2275-81. PubMed ID: 21562496
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
[TBL] [Abstract][Full Text] [Related]
13. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
Hugle M; Fulda S
Cancer Lett; 2015 Apr; 360(1):1-9. PubMed ID: 25637161
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Graab U; Hahn H; Fulda S
Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
16. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Unland R; Clemens D; Heinicke U; Potratz JC; Hotfilder M; Fulda S; Wardelmann E; Frühwald MC; Dirksen U
Anticancer Drugs; 2015 Sep; 26(8):843-51. PubMed ID: 26053276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]